Publications by authors named "M Aho"
Article Synopsis
- * Manually labeling unstructured medical reports for DR analysis is labor-intensive, leading to the development of DR-GPT, a large language model designed to classify DR severity from these reports.
- * DR-GPT demonstrated high accuracy in severity classification and improved the performance of image classifiers when its annotations were combined with fundus images, showcasing the potential of AI in healthcare.
Naloxone is an effective FDA-approved opioid antagonist for reversing opioid overdoses. Naloxone is available to the public and can be administered through intramuscular (IM), intravenous (IV), and intranasal spray (IN) routes. Our literature review investigates the adequacy of two doses of standard IM or IN naloxone in reversing fentanyl overdoses compared to newer high-dose naloxone formulations.
View Article and Find Full Text PDFNaloxone is a U.S. Food and Drug Administration (FDA) approved opioid antagonist for reversing opioid overdoses.
View Article and Find Full Text PDFBackground: The aim of this study was to report the outcomes of sacral neuromodulation (SNM) in chronic pelvic pain (CPP) patients in the Finnish national cohort.
Methods: This was a register-based retrospective study, involving all the centers that provide SNM treatment in Finland. The data of all patients treated with SNM for CPP were gathered from Oulu-, Turku-, Tampere- and Helsinki University Hospitals, as well as Jyväskylä and Seinäjoki Central Hospitals.
Article Synopsis
- * Only 1.1% of the IDPs were found to be upgraded to ductal carcinoma in situ or invasive carcinoma during excision, indicating a low risk of malignancy.
- * Factors influencing upgrade rates included age, size of the papilloma on biopsy, and presence of additional ultrasound masses, suggesting that monitoring rather than immediate surgery may be sufficient for certain benign cases.